ArticleEndocrine pathology2011
Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence.
Article in Endocrine pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 6 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- The dual oncogenic and protective roles of hashimoto's thyroiditis in papillary thyroid carcinoma: a cohort-based meta-analysis.World journal of surgical oncology · 2026Pooled it
- Hashimoto's thyroiditis reduces central lymph node metastasis risk in papillary thyroid microcarcinoma: an integrated meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Radioactive iodine therapy for thyroid cancer coexisting with Hashimoto's thyroiditis: a systematic review and meta-analysis.The British journal of radiology · 2024Pooled it
- Hashimoto Thyroiditis and Mortality in Patients with Differentiated Thyroid Cancer: The National Epidemiologic Survey of Thyroid Cancer in Korea and Meta-Analysis.Endocrinology and metabolism (Seoul, Korea) · 2024Pooled it
- Hashimoto's Thyroiditis: A "Double-Edged Sword" in Thyroid Carcinoma.Frontiers in endocrinology · 2022Pooled it
- Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis.PloS one · 2022Pooled it
- Impact of Hashimoto Thyroiditis on Long-Term Outcomes in Differentiated Thyroid Carcinoma.Cancers · 2026Article
- Lower invasiveness of papillary thyroid carcinoma associated with Hashimoto's thyroiditis: evidence from AJCC 8th-edition stratification and a dose-response relationship with autoantibody titers.Frontiers in endocrinology · 2026Article
- Is conformal thyroidectomy feasible? A 5-10-year follow-up study of residual thyroid in 2512 cases after thyroidectomy.World journal of surgical oncology · 2025Article
- Impact of Hashimoto's thyroiditis on ultrasound diagnosis of papillary thyroid carcinoma: a retrospective study.Frontiers in oncology · 2025Article
- Mechanisms underlying the promotion of papillary thyroid carcinoma occurrence and progression by Hashimoto's thyroiditis.Frontiers in endocrinology · 2025Review
- Clinical and molecular impact of concurrent thyroid autoimmune disease and thyroid cancer: From the bench to bedside.Reviews in endocrine & metabolic disorders · 2024Review
- BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.Frontiers in endocrinology · 2024Article
- A multivariable model of ultrasound and biochemical parameters for predicting high-volume lymph node metastases of papillary thyroid carcinoma with Hashimoto's thyroiditis.Frontiers in endocrinology · 2024Article
- Evaluating the Influence of Hashimoto's Thyroiditis on Clinico-Pathological Characteristics and Prognostic Outcomes of Middle Eastern Differentiated Thyroid Carcinoma.International journal of endocrinology · 2024Article
- Inflammatory and Infectious Disorders in Endocrine Pathology.Endocrine pathology · 2023Review
- Article
- Papillary thyroid cancer with Hashimoto's thyroiditis attenuates the tumour aggressiveness through the up-regulation of E-cadherin and TGF-β expression.Clinical and experimental medicine · 2023Article
- Hashimoto's Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma.Cancers · 2023Article
- Association between papillary thyroid carcinoma and lymphocytic thyroiditis: A retrospective study.Oncology letters · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) are the most common differentiated thyroid cancers. Previous studies report that Hashimoto's thyroiditis (HT) concomitant with PTC is unusual and improves prognosis compared to classical PTC. Few previous studies address FTC concomitant with HT. In this study, we retrospectively analyzed data from one institution and compared clinical presentations and results of treatment of PTC and FTC with and without HT. In addition, studies comparing presentation and long term follow-up prognosis in classical PTC and FTC were conducted. A total of 1,788 PTC patients and 209 FTC patients underwent thyroidectomy with or without lymph node dissection and follow-up at Chang Gung Medical Center in Linkou, Taiwan. All thyroid carcinomas were pathologically classified according to World Health Organization criteria. Histological patterns of PTC were categorized as classical PTC, or PTC with HT. Follicular thyroid carcinoma patients were categorized as FTC or FTC with HT. The dataset contained a total of 1,703 PTC cases categorized as classical PTC, 85 cases of PTC with HT, 201 cases of FTC and eight cases of FTC with HT. Analysis of Classification of Malignant Tumors (TNM) stage revealed a higher percentage of classical PTC in stage IV than HT group (12.03% vs. 4.70%). Mean tumor size of classical PTC was larger than HT group. Although 42.3% of FTC cases presented with distant metastases, no cases of FTC with HT presented with distant metastasis. Cancer-specific mortality was higher in classical PTC group than in PTC with HT. There was 53.2% of FTC without HT assigned recurrent status, and six of them died of thyroid cancer. No cancer mortality or recurrence in HT with FTC. PTC and FTC with HT presented with better clinical stage and better prognosis after same therapeutic modality. In conclusions, both PTC and FTC with HT have less aggressive clinical presentation and better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.